EMVision Expands Pivotal Trial for Stroke Diagnosis Device

EMvision Medical Devices Ltd. ( (AU:EMV) ) has shared an update.

EMVision Medical Devices Ltd has announced the activation of two additional sites for its pivotal trial of the emu™ bedside brain scanner, with Mount Sinai in New York and Liverpool Hospital in Sydney joining the study. These activations bring the total to five sites, with a sixth to follow, as part of efforts to validate the device’s diagnostic performance for FDA De Novo clearance. The trial aims to demonstrate the scanner’s potential to improve stroke diagnosis and treatment outcomes by enabling rapid differentiation of stroke types at the point-of-care.

More about EMvision Medical Devices Ltd.

EMVision Medical Devices Ltd is a company in the medical device industry, focusing on developing innovative diagnostic tools. Their primary product is the emu™ bedside brain scanner, designed for point-of-care stroke diagnosis. The company is engaged in pivotal trials to support FDA De Novo clearance, aiming to enhance stroke care through rapid diagnosis and intervention.

Average Trading Volume: 43,759

Technical Sentiment Signal: Sell

Current Market Cap: A$145.4M

For an in-depth examination of EMV stock, go to TipRanks’ Stock Analysis page.